Clinical Publications |
Scientific Publications |
February 2024 |
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANS1::ARC1A) alteration: A case report with insights on the molecular landscape Fontana D et al. Ann Hematol, February 2024 (epub ahead of print) |
Integrated gene co-expression network analysis and experimental validation revealed potential targets of human urine extract CDA-II in treating chronic myeloid leukemia Jiang L et al. Genomics, February 2024 (epub ahead of print) – open access publication |
Identification and clinical implications of recurrent PAX5::MLLT3 fusion in lymphoid blastic phase chronic myeloid leukemia Wang L et al. Int J Lab Hematol, February 2024 (epub ahead of print) |
Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models Ansari AS et al. J Control Release, February 2024 (epub ahead of print) |
Quantitative detection of T315I mutations of BCR::ABL1 using digital droplet polymerase chain reaction Mu H et al. Hematol Transfus Cell Ther, February 2024 (epub ahead of print) – open access publication |
AS1041, a novel derivative of marine natural compound Aspergiolide A induces senescence of leukemia cells via oxidative stress-induced DNA damage and BCR-ABL degradation Lu X et al. Biomed Pharmacother, February 2024 – open access publication |
HIF2-alpha expression in CML patients receiving hydroxyurea prior to imatinib that achieved major molecular response (MMR) versus in those not achieving MMR Rinaldi I et al. J Blood Med, February 2024 (epub ahead of print) – open access publication |
Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib Klaihmon P et al. Sci Rep, February 2024 (epub ahead of print)
|
|
The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia - Review El-Tanani M et al. Pathol Res Pract, February 2024 – open access publication |
January 2024 |
Chronic myeloid leukemia with two rare fusion gene transcripts of atypical BCR::ABL: A Case report and literature review Li Y et al. Medicine (Baltimore), January 2024 – open access publication |
Circ-SIRT1 upregulated ATG12 to facilitate imatinib resistance in CML through interacting with EIF4A3 Zhang R et al. Gene, January 2024 |
Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide in chronic myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation from an unrelated or mismatched related donor: A Comparative study from the Chronic Malignancies Working Party of the EBMT (CHWP-EBMT) Ortí G et al. Transplant Cell Ther, January 2024 – open access publication |
Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia – Review Sun J et al. Int J Biol Sci, January 2024 – open access publication |
Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors Velmaat L and Cortes J. Blood, January 2024 (epub ahead of print) |
Role of miRNAs to control the progression of chronic myeloid leukemia by their expression levels Bansal M et al. Med Oncol, January 2024 |
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials Jabbour E et al. Leukemia, January 2024 (epub ahead of print) – open access publication |
Extracellular vesicles in the chronic myeloid leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules - Review Bernardi S et al. Front Oncol, January 2024 – open access publication |
Maximizing the value of chronic myeloid leukemia management using tyrosine kinase inhibitors in the USA: Potential determinants and consequences of healthcare resource utilization and costs, with proposed optimization approaches Lipton JH. Clin Drug Investig, January 2024 (epub ahead of print) |
Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation Boucher L et al. Leuk Res, January 2024 (epub ahead of print) |
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to J.P Gale and J. Chen Pfirrmann M et al. Leukemia, January 2024 (epub ahead of print) – open access publication |
Identification and validation of hub genes and molecular classifications associated with chronic myeloid leukemia Zhong F et al. Front Oncol, January 2024 – open access publication |
Treatment-free remission after a second TKI discontinuation attempt in patients with chronic myeloid leukemia re-treated with Dasatinib – Interim results from the DAstop2 trial Flygt H et al. Leukemia, January 2024 (epub ahead of publication) – open access publication |
Immortalised chronic myeloid leukemia (CML) derived mesenchymal stromal cells (MSC) line retains the immunomodulatory and chemoprotective properties of CML patient-derived MSCs Benjamin ESB Cell Signal, January 2024 (epub ahead of print) |
Safety and efficacy of asciminib in a chronic myloid leukemia patient with chronic kidney disease: A case report Alshurufa A et al. Case Rep Oncol, January 2024 – open access publication |
Multidrug resistance phenotype and its relation to stem cell characteristics in chronic myeloid leukemia Lettnin AP et al. Gene, January 2024 |
A review of the therapeutic role of bosutinib in chronic myeloid leukemia – Review Kantarjian HM et al. Clin Lymphoma Myeloma Leuk, January 2024 |
Activating p53 abolishes self-renewal of quiescent leukemic stem cells in residual CML disease Scott MT et al. Nat Commun, January 2024 – open access publication |
Safety and efficacy of tyrosine kinase inhibitors in very elderly patients (≥ 75 years) with chronic myeloid leukemia Costa A et al. J Clin Med, January 2024 – open access publication |
Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model Imeri J et al. Front Immunol, January 2024 – open access publication |
Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript Dereme J et al. Ann Hematol, January 2024 (epub ahead of print) |
|
What do atomic bomb survivors teach us about treatment-free remission in people with chronic myeloid leukemia Radivoyevitch T et al. Leukemia, January 2024 – open access publication |
|
How to individualized therapy after failing milestones in chronic myeloid leukemia: weighting late response and early death from CML against risk of alternative therapy Hehlmann R and Lauseker M. Leukemia, January 2024 (epub ahead of print) – open access publication |
|
Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL fusion gene in Ph-positive leukemias Sponseiler I et al. Am J Hematol, January 2024 – open access publication |
|
December 2023 |
CML and the WHO: Why? Berman E et al. J Clin Oncol, December 2023 (epub ahead of print) |
Precision isolation of circulating leukemia cells in chronic myelogenous leukemia patients using a novel microfluid device and its clinical applications Ouyaung D et al. Cancers(Basel), December 2023 – open access publication |
Estimated savings after stopping tyrosine kinase inhibitor treatment among patients with CML Winn AN et al. JAMA Netw Open, December 2023 – open access publication |
Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis Wu A et al. Leukemia, December 2023 |
Aleukemic chronic myeloid leukemia without neutrophilia and thrombocytosis at initial presentation: a Report from the BCR::ABL1 Pathology Group Rivera D et al. Mod Pathol, December 2023 (epub ahead of print) – open access publication |
The SNP rs460089 in the gene promoter of the drug-transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib Machova Polakova K et al. Leukemia, December 2023 (epub ahed of print) – open access publication |
Accelerated-phase CML: de novo and transformed Shanmunagathan N and Hughes TP. Hematology Am Soc Hematol Educ Program, December 2023 – open access publication |
A review on characterization of BCR-ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes Zenebe B et al. Hematology Review, December 2023 – open access publication
|
Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ≥ 2 tyrosine kinase inhibitors: a systematic literature review Atallah E et al. Ther Adv Hematol, December 2023 – open access publication |
C-Myc inhibition intensified the anti-leukemic properties of imatinib in chronic myeloid leukemia cells Zehtabcheh S et al. Mol Biol Rep, December 2023 |
Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML Working Group) – in French Réa D et al. Bull Cancer, December 2023 (epub ahead of print) – open access publication
|
The role of CSE1L silencing in the regulation of proliferation and apoptosis via the AMPK/mTor signaling pathway in chronic myeloid leukemia Liu XY et al. Hematology, December 2023 – open access publication |
Resistance mutations in CML and how we approach them - Review Soverini S et al. Hematology Am Soc Educ Program, December 2023 – open access publication |
Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia Yin L et al. Hematology, December 2023 – open access publication |
SOHO State of the art updates and next questions: Chronic myeloid leukemia and pregnancy: Per Aspera ad Astra” - Review Abruzzese E et al. Clin Lymphoma Myeloma Leuk, December 2023 (epub ahead of print) |
miR-181a plays a tumor-suppressor role in chronic myeloid leukemia CD34+ cells partially via SERPINE1 Zhang X et al. Cell Mol Life Sci, December 2023 - open access publication |
How to improve treatment-remission eligibility in CML? Review Costa A and Breccia M. Br J Haematol, December 2023 (epub ahead of print) – open access publication |
Osimertinib covalently binds to CD34 and eliminates progenitor cells Xia L et al. Cancer Res, December 2023 (epub ahead of print) |
The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia Liu L et al. Hematology, December 2023 – open access publication |
Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells Yang Y et al. Hematology, December 2023 – open access publication |
Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy, The Surveillance, Epidemiology, and End Results database, 2000-2019 Sasaki K et al. Cancer, December 2023 |
|
Sex-specific incidence of hepatitis B virus flares among BCR-ABL tyrosine kinase inhibitor users in Taiwan Wang LY et al. Pharmacoepidemiol Drug Saf, December 2023 |
|
Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans Hofmann J et al. Leukemia, December 2023 – open access publication |
|
Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML Kongruang A et al. Hematology, December 2023 – open access publication |
|
An update of the management of advanced phase chronic myeloid leukemia – Review Short NJ et al. Curr Hematol Malig Rep, December 2023 |
|
Evaluation of real-world versus clinical trial outcome of tyrosine kinase inhibitor therapy for chronic myeloid leukemic Collins JB et al. J Oncol Pharm Pract, December 2023 (epub ahead of print) – open access publication |
|
Cardiovascular adverse events of tyrosine kinase inhibitors in chronic myeloid leukemia: Clinical relevance, impact on outcome, preventive measures and treatment strategies – Review Iurlo A et al. Curr Treat Options Oncol, December 2023 (epub ahead of print) |
|
Exploration of treatment-free remission in CML, based on molecular monitoring – Review Zhang Z et al. Cancer Med, December 2023 (epub ahead of print) – open access publication |
|
November 2023 |
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia Cross NCP et al. Leukemia, November 2023 – open access publication |
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation Huuhtanen J et al. Leukemia, November 2023 (epub ahead of print) – open access publication |
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO Study Zambrotta GPM et al. Am J Hematol, November 2023 – open access publication |
Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia Shin JE et al. Mol Cancer, November 2023 – open access publication |
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: Results from the phase 4 BYOND study Rosti G et al. Leukemia, November 2023 (epub ahead of print) – open access publication |
Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment Häselbarth L et al. BMC Cancer, November 2023 – open access publication |
Survival with chronic myeloid leukemia after failing milestones Lauseker M et al. Leukemia, November 2023 – open access publication |
|
What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia? Kantarjian HM Leukemia, November 2023 |
|
The new systematic coronary risk evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib and ponatinib Mulas O et al. Ann Hematol, November 2023 |
|
Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor Park H et al. Ther Adv Hematol, November 2023 – open access publication |
|
Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients Rafiq Mohammed A et al. Gene, November 2023 |
|
October 2023 |
Viral infections and incidence of reactivation in chronic myeloid leukemia patients – Review Aldapt MB et al. Oncology, October 2023 (epub ahead of print) |
Transporter-mediated cellular distribution of tyrosine kinase inhibitors as a potential resistance mechanism in chronic myeloid leukemia - Review Verhagen NE et al. Pharmaceutics, October 2023 – open access publication |
Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia: a systematic review and network analysis – Review Zhang S et al. Expert Opin Drug Saf, October 2023 (epub ahead of print) |
Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for suppression of chronic myeloid leukemia Han H et al. Biochem Pharmacol, October 2023 (epub ahead of print) |
Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions Larfors G et al. Eur J Haematol, October 2023 – open access publication |
A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells Zhang X et al. Cell Mol Biol Lett, October 2023 – open access publication |
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy Khadadah FM et al. Leuk Res, October 2023 |
AZD-7648, a DNA-PK inhibitor, induces DNA damage, apoptosis, and cell cycle arrest in chronic and acute myeloid leukemia cells Lapa BS et al. Int J Mol, October 2023 – open access publication |
Revisiting six established practices in the treatment of chronic myeloid leukemia - Review Kantarjian HM et al. Lancet Haematol, October 2023 |
Deciphering potential molecular signatures to differentiate acute myeloid leukemia (AML) with BCR::ABL1 from chronic myeloid leukemia (CML) in blast crisis Boucher L et al. Int J Mol, October 2023 – open access publication |
Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results Gener-Ricos C et al. Clin Lymphoma Myeloma Leuk, October 2023 |
|
Spontaneous remission in a patient with chronic myeloid leukemia: A Case Report Alshurufa A et al. Case Rep Oncol, October 2023 – open access publication |
|
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia Efficace F et al. Cancer, October 2023 (epub ahead of print) |
|